Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial
Tavapadon, a novel, investigational, selective D1/D5 agonist with once-daily oral dosing, provides clinically meaningful and sustained benefit adjunctive to levodopa and has a favourable safety profile in patients with Parkinson’s disease (PD) experiencing off fluctuations, according to findings of the TEMPO-3 trial.